StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck NuvaRing by Year

NuvaRing (etonogestrel/ethinyl estradiol, legacy pre-Organon spin-off) — International reported growth YoY (%) (%)

Merck NuvaRing: -24.0% in FY2019, down 16.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, FY2019
-24.0%
Period ended Dec 31, 2019
Change on a year earlier
-16.0 pts
-8.0% in FY2018
History
3 years
Since FY2017
Sources
3
Documents cited below

Where the FY2019 figure comes from

“|| NuvaRing | 879 | 902 | -3 | 742 | 722 | 3 | 136 | 180 | -24”

Source: Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNuvaRing (etonogestrel/ethinyl estradiol, legacy pre-Organon spin-off) — International reported growth YoY (%) (%)Year on yearSource
FY2019Dec 31, 2019-24.0%-16.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 2018-8.0%-6.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2017Dec 31, 2017-2.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck NuvaRing (%), annual FY2017–FY2019 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-nuvaring-intl-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.